{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:47:27Z","timestamp":1778500047232,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2004,8,12]],"date-time":"2004-08-12T00:00:00Z","timestamp":1092268800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/s00296-004-0467-8","type":"journal-article","created":{"date-parts":[[2004,8,11]],"date-time":"2004-08-11T07:44:59Z","timestamp":1092210299000},"page":"406-410","source":"Crossref","is-referenced-by-count":89,"title":["The effect of infliximab on extraintestinal manifestations of Crohn\u2019s disease"],"prefix":"10.1007","volume":"25","author":[{"given":"Ilana","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Caspi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dror","family":"Yeshurun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Dotan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Yaron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ori","family":"Elkayam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,8,12]]},"reference":[{"key":"467_CR1","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1572-0241.2001.03756.x","volume":"96","author":"Bernstein","year":"2001","unstructured":"Bernstein CN, Blanchard JF, Rawsthorne P et al (2001) The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol 96:1116\u20131122","journal-title":"Am J Gastroenterol"},{"key":"467_CR2","unstructured":"Wollbeim FA (2001) Enteropathic arthritis. In: Ruddy S, Harris ED, Sledge CB (eds) Kelley\u2019s textbook of rheumatology, 6th edn. Saunders, Philadelphia, pp\u00a01081\u20131088"},{"key":"467_CR3","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/003655201317097173","volume":"36","author":"Salvarani","year":"2001","unstructured":"Salvarani C, Viachonikolis IG, van der Heijde DM et al (2001) Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients. Scand J Gastroenterol 36:1307\u20131313","journal-title":"Scand J Gastroenterol"},{"key":"467_CR4","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1093\/rheumatology\/40.11.1256","volume":"40","author":"Palm","year":"2001","unstructured":"Palm O, Moum B, Jahnsen J, Gran JT (2001) The prevalence and incidence of peripheral arthritis in patients with inflammatory bowel disease, a prospective population based study (the IBSEN study). Rheumatology 40:1256\u20131261","journal-title":"Rheumatology"},{"key":"467_CR5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004836-199607000-00009","volume":"23","author":"Veloso","year":"1996","unstructured":"Veloso FT, Carvalho J, Magro F (1996) Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 23:29\u201334","journal-title":"J Clin Gastroenterol"},{"key":"467_CR6","first-page":"1995","volume":"49","author":"Badelon","year":"1999","unstructured":"Badelon I (1999) Eye and spondyloarthropathies. Rev Prat 49:1995\u20131998","journal-title":"Rev Prat"},{"key":"467_CR7","first-page":"883","volume":"142","author":"Udvardy","year":"2001","unstructured":"Udvardy M, Altorjay I, Palatka K (2001) Hematologic aspects of inflammatory bowel disease. Orv Hetil 142:883\u2013886","journal-title":"Orv Hetil"},{"key":"467_CR8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1572-0241.2001.03612.x","volume":"96","author":"Ricart","year":"2001","unstructured":"Ricart E, Panaccione R, Loftus EV et al (2001) Infliximab for Crohn\u2019s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 96:722\u2013729","journal-title":"Am J Gastroenterol"},{"key":"467_CR9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","volume":"116","author":"D\u2019haens","year":"1999","unstructured":"D\u2019haens G, Van Deventer S, Van Hogezand R et al (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn\u2019s disease: A European multicenter trial. Gastroenterology 116: 1029\u20131035","journal-title":"Gastroenterology"},{"key":"467_CR10","doi-asserted-by":"crossref","first-page":"10235","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, Van Deventer SJ et al (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s disease cA2 study group. N Engl J Med 337:10235","journal-title":"N Engl J Med"},{"key":"467_CR11","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 340:1398\u20131405","journal-title":"N Engl J Med"},{"key":"467_CR12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00124743-200104000-00002","volume":"7","author":"Ellman","year":"2001","unstructured":"Ellman MH, Hanauer S, Sitrin M et al (2001) Crohn\u2019s disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol 7:67\u201371","journal-title":"J Clin Rheumatol"},{"key":"467_CR13","first-page":"930","volume":"37","author":"Tan","year":"2001","unstructured":"Tan MH, Gordon M, Lebwohl O et al (2001) Improvement of pyoderma gangrenosum and psoriasis associated with Crohn\u2019s disease with anti-tumor necrosis factor a monoclonal antibody. Arch Dermatol 37:930\u2013933","journal-title":"Arch Dermatol"},{"key":"467_CR14","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jama.284.12.1546","volume":"284","author":"Hughes","year":"2000","unstructured":"Hughes AP, Jackson JM, Callen JP (2000) Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 284:1546\u20131548","journal-title":"JAMA"},{"key":"467_CR15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1155\/1999\/506915","volume":"13","author":"Yoshida","year":"1999","unstructured":"Yoshida EM (1999) The Crohn\u2019s disease activity index, its derivatives and the inflammatory bowel disease questionnaire: a review of instruments to assess Crohn\u2019s disease. Can J Gastroenterol 13:65\u201373","journal-title":"Can J Gastroenterol"},{"key":"467_CR16","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(80)91577-9","volume":"1","author":"Harvey","year":"1980","unstructured":"Harvey RF, Bradshaw JM (1980) Measuring Crohn\u2019s disease activity. Lancet 1:1134\u20131135","journal-title":"Lancet"},{"key":"467_CR17","doi-asserted-by":"crossref","unstructured":"Van Deventer SJ (1999) Targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn\u2019s disease\u2014the mechanisms of action of infliximab. Aliment Pharmacol Ther [Suppl\u00a04]:3\u20138","DOI":"10.1046\/j.1365-2036.1999.00024.x"},{"key":"467_CR18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1517\/13543784.10.1.21","volume":"10","author":"Toussirot","year":"2001","unstructured":"Toussirot E, Wendling D (2001) Therapeutic advances in ankylosing spondylitis. Expert Opin Invest Drugs 10:21\u201329","journal-title":"Expert Opin Invest Drugs"},{"key":"467_CR19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B","volume":"44","author":"Baeten","year":"2001","unstructured":"Baeten D, Kruithof E, Van den Bosch F et al (2001) Immunomodulatory effects of anti-tumor necrosis factor a therapy on synovium in spondyloarthropathy. Histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 44:186\u2013195","journal-title":"Arthritis Rheum"},{"key":"467_CR20","first-page":"118","volume":"29","author":"Brandt","year":"2002","unstructured":"Brandt J, Haibel H, Reddig J et al (2002) Successful short-term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 29:118\u2013122","journal-title":"J Rheumatol"},{"key":"467_CR21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1517\/14656566.2.1.85","volume":"2","author":"Keyser","year":"2001","unstructured":"Keyser FD, Mielants H, Veys EM (2001) Current use of biological for the treatment of spondyloarthropathies. Expert Opin Pharmacother 2:85\u201393","journal-title":"Expert Opin Pharmacother"},{"key":"467_CR22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0952-7915(00)00269-7","volume":"13","author":"Taylor","year":"2001","unstructured":"Taylor PC, Williams RO, Maini RN (2001) Immunotherapy for rheumatoid arthritis. Curr Opin Immunol 13:611\u2013616","journal-title":"Curr Opin Immunol"},{"key":"467_CR23","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","volume":"43","author":"Brandt","year":"2000","unstructured":"Brandt J, Haibel H, Cornely D et al (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346\u20131352","journal-title":"Arthritis Rheum"},{"key":"467_CR24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.59.6.428","volume":"59","author":"Van","year":"2000","unstructured":"Van den Bosch F, Kruithof E, Baeten D et al (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59:428\u2013433","journal-title":"Ann Rheum Dis"},{"key":"467_CR25","first-page":"1605","volume":"28","author":"Stone","year":"2001","unstructured":"Stone M, Salonen D, Lax M et al (2001) Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 28:1605\u20131614","journal-title":"J Rheumatol"},{"key":"467_CR26","doi-asserted-by":"crossref","unstructured":"Hadi A, Hickling P, Brown M, Al-Nahhas A (2002) Scintigraphic evidence of effect of infliximab on disease activity in ankylosing spondylitis. Rheumatology (Oxford) 41:114\u2013116","DOI":"10.1093\/rheumatology\/41.1.114"},{"key":"467_CR27","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 359:1187\u20131193","journal-title":"Lancet"},{"key":"467_CR28","first-page":"959","volume":"29","author":"Maksymowych","year":"2002","unstructured":"Maksymowych WP, Jhangri GS, Lambert RG et al (2002) Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29:959\u2013965","journal-title":"J Rheumatol"},{"key":"467_CR29","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","volume":"346","author":"Gorman","year":"2002","unstructured":"Gorman JD, Sack KE, Davis JC (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor. N Engl J Med 346:1349\u20131356","journal-title":"N Engl J Med"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-004-0467-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-004-0467-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-004-0467-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:15:15Z","timestamp":1559042115000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-004-0467-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1007\/s00296-004-0467-8","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,12]]}}}